Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Lung Cancer. 2012 Dec 27;79(3):193–197. doi: 10.1016/j.lungcan.2012.12.002

Table 3.

Proportion of Family History of Lung versus Other Cancers by Selected Tumor Genotype

EGFR mutation + KRAS mutation plus ALK translocation + ^ EGFR WT/KRAS WT/ALK FISH negative
(n=53) (n=24) p (n=29) p
Lung Cancer 22 (41.5%) 4 (17%) 0.039 9 (31%) 0.475
Other Cancers 31 (58.5%) 20 (83%) 20 (67%)
+

one patient with a tumor with EGFR mutation and KRAS mutation was excluded from analysis

^

one patient with a tumor with ALK translocation and KRAS mutation was excluded from analysis

EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization